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Despite the statistical evidence that a more favorable prognosis is associated with
a greater magnitude oflymphocyte infiltration, it remains uncertain whethertumor
infiltrating lymphocytes (TIL)' play any significant role in tumor immunity . We ini-
tially reported that TIL from metastatic melanoma were predominantly CD8+ T
cells that differentiated in the presence of rIL-2 into CTL, with cytolysis restricted
to autologous tumor cells (1) . Immunotherapy with rIL2 alone or rIL-2 and lympho-
kine-activated killer (LAK) cells resulted in marked tumor regression in some
metastatic melanoma patients for whom there is no other effective therapy (2, 3) .
Identification of effector cells responsible fortumor regression is essential to under-
standing host-tumor interactions, and may be important for increasing the ther-
apeutic efficacy of the treatment and decreasing toxicity and complexity. We and
others have reported that most ofLAK activity is derived from bloodNK cells (4-9) .
TIL from metastatic melanoma usually do not contain NK cells (1, 10) . However,
T cells predominate in TIL from metastatic melanomas (1, 10), and may be acti-
vated by rIL-2 toCTL specific for autologous tumor targets (1, 10) . For these reasons,
TIL, rather than rIL-2-activated NK cells (LAK cells), may be more appropriate
as effector cells for tumor regression in melanoma patients . Furthermore, the target
specificity of rIL-2-activated TIL makes them superior to LAK cells in adoptive im-
munotherapy (1, 4-12) . A serious obstacle in adapting rIL-2-activated TIL for im-
munotherapy is the difficulty in obtaininglarge numbers ofeffector cells . The difficulty
resides in (a) limited numbers of TIL recovered from surgical specimens and (b)
limited knowledge about the nature and activation ofTIL . In this study, we report
thatTIL from metastatic melanoma increased in number by >1,000-fold when cul-
tured with rIL-2 alone . Activated TIL displayed potent autologoustumor cell-specific
CTL activity and theTCRa/(3 was involved in target cell recognition . IL-2 receptor
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expression on rIL-2-activated TIL is upregulated by stimulation with fresh autolo-
gous melanoma cells.
Materials and Methods
Preparation of Cells.
￿
Single-cell suspensions of TIL and tumor cells were prepared from
12 different surgical specimens from 12 patients with metastatic melanoma, 5 tumors from
5 primary sarcoma patients, and 3 tumors from 3 primary renal cell carcinoma patients using
collagenase, hyaluronidase, and DNase as reported previously (1). Pathology examination
of the tumor specimens confirmed the diagnosis of melanoma, sarcoma, or renal cell carci-
noma in all tumor specimens used in this study. Necrotic areas or tissues surrounding the
tumor were carefully removed before the preparation ofthe cells. Macroscopic examination
revealed that the specimens used in this study contained only tumor mass. Ranges of the
weight of melanoma tumor specimen were <1 g in patients 3, 5, 7, 8, 10, and 11, between
1 and 10 g in patients 4, 6, 9, and 12, and more than 10 g in patients 1 and 2 . Lymph nodes
(LN) with melanoma metastasis from six patients were processed similarly. None of the pa-
tients had prior chemotherapy or radiation. Cell viability exceeded 80% . Lymphoid cells
were discriminated from tumor cells by cell size, morphology, and the brownish cytoplasmic
pigentation of the melanoma cells (1). mAb specific for human lymphocytes (anti-CD3,
-CD4, -CD8) or anti-CD16 mAb were used to confirm the identity of these cells. Heparinized
peripheral bloodwas obtained from patients with metastatic melanoma or from healthy volun-
teers. PBMC were harvested over a Ficoll-Hypaque density cushion as described (4).
Cell Cultures and Cytokines.
￿
Suspensions of TIL and tumor cells were washed twice and
resuspended at 2-10 x 105 cells/ml in RPMI 1640 medium supplemented with 10% FCS
(GIBCO Laboratories, Grand Island, NY) (medium) and 20 U/ml or 200 U/ml of rIL-2,
and cultured at 37°C with 5% C02 in 24-well tissue culture plates (Corning Glass Works,
Corning, NY; 2 ml/well). Half the volume o£ each well was replenished with fresh medium
containing rIL-2 every 3-5 d, and the density of cells was maintained at <1-2 x 106 cells/ml
during the entire culture period. In some experiments, cells cultured with rIL-2 were applied
to a Ficoll-Hypaque density cushion and live cells were collected from the interface and sub-
sequently incubated with rIL-2. Human rIL-2 and rIFN-y were kindly provided by Biogen
Corp. (Boston, MA) and had sp act of 3.6 x 106 U/mg and 1 .2 x 10' U/mg of protein,
respectively (4, 5). rIL-1, rIL-3, and rIL-4 were purchased from Genzyme, Inc. (Boston, MA).
CultureofPBMC with Autologous TumorCellsandrIL-2.
￿
PBMC from patients with metastatic
melanoma (n = 4) were incubated with autologous tumor cells at a responder/stimulator
ratio of 2:1 in the presence of 20 U/ml rIL-2 . Half the volume of medium was replenished
with fresh media containing 20 U/ml rIL-2 every 3-5 d. Tumor cells were not irradiated.
PBMC were not restimulated with autologous tumor cells.
TreatmentofCells.
￿
rIL-2-activated TIL were treated with mAb for 30 min at 4'C, followed
by incubation with low-toxic H rabbit complement (CedarlaneLab., Ontario, Canada) (15%
in medium) for 30 min at 37'C as reported previously (4).
Partial Purification of TIL.
￿
For the experiments to detect cytotoxicity in freshly isolated
TIL, TIL were partially purified from tumor cells by a discontinuous Percoll density gra-
dient centrifugation as reported previously (1). Briefly, cell suspensions were applied to a
Percoll discontinuous gradient (five different concentrations, 38.6, 43.1, 47.6, 52 .1, and 56.6%)
and centrifuged for 45 min at 400 g. Partially purified TIL (70-85 % purity) were recovered
from the interface of 52.1 and 56.6% Percoll solution, and used as effector cells to detect
cytotoxicity against autologous tumor cells.
Stimulation ofLong-term Cultured TIL.
￿
Long-term (>60 d) cultured TIL were stimulated
at an effector/stimulator ratio of 1:1 with fresh melanoma tumor cells that were irradiated
(10,000 rad) using a Mark I Cesium 137 source (Nuclear Associates, Glendale, CA).
mAb.
￿
Murine hybridoma cells producing anti-CD3, -CD4, -CD8, and anti-HLA-DR mAb
(L243) were purchased from American Type Culture Collection (ATCC), Rockville, MD.
Murine hybridoma cells producing an anti-HLA-A, -B, -C mAb were kindly supplied by
Dr. C. Y. Wang. Ascitic fluid containing mAbs was prepared by injecting hybridoma cellsITOH ET AL.
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into BALB/c mice, as reported previously (4). Purified IgG ofanti-TCRas mAb (WT31 mAb)
(1 mg/ml) was kindly provided by Dr. WJ. M. Tax (13).
Analysis ofLymphocyte Surface Markers.
￿
FITC-conjugated Leu series of mAb (anti-Leu-4,
Leu-3a, Leu-2a, Leu-7, and Leu-11a) and phycoerythrin (PE)-conjugated anti-Leu 4 and
anti-IL-2 receptor mAb (antiTac mAb) were purchased from Becton DickinsonCo. (Moun-
tain View, CA). Lymphocytes were incubated with mAb at 4oCfor 30 min, andthen antigen
expression was analyzed usingflow cytometry (EPICS C; Coulter, Hialeah, FL) as reported
previously (4, 5). To detect the percentage of WT31' cells, TIL were incubated with 10 ug/ml
of anti-WT31 mAb for 30 min at 4oC, followed by staining with FITC-conjugated F(ab')z
fragments of goat anti-mouse IgG (Cooper Laboratories, Cochranville, PA).
"Cr-release Assay andAssayfor Proliferative Response.
￿
A 4-h 5'Cr-release assay was used to
detect cytotoxic activity as described previously (1, 4-6). Cryopreserved, noncultured tumor
cells, K562 targetsor unstimulated PBMC from melanoma patients were used as target cells.
The spontaneous release did notexceed 25% ofmaximum release. The percentage of specific
lysiswas calculated as described (1). Thelevel of cytotoxicity was also expressed as lyticunits
(LU) per 106 effector cells. One LU was defined as the number of effector cells that lysed
30% of 104 target cells as reported previously (5). The proliferative response wasmeasured
by culturing 105 lymphocytes/well for 3 d in flat-bottomed microtiter plates with and without
rIL-2. Tritiated thymidine (0.5 pCi/well; New England Nuclear, Boston, MA) was added
6 h before harvesting.
Limiting Dilution Analysis.
￿
Limiting dilution analysis of TIL was carried out according
to themethodsdescribed by Moretta et al. (14), with a slight modification. Briefly, different
numbers (8, 4, 2, 1, and 0.5) of fresh TIL per well were incubated in 96-well U-bottomed
microplates in RPMI medium supplemented with 10% FCS, 200 U/ml rIL-2, 10 Pg/mlPHA
(Sigma Chemical Co., St. Louis, MO) and 10 ng/ml PMA (Sigma Chemical Co.) in the pres-
ence of irradiated (7,000 rad) PBMC from two different healthy donors (2 x 105
PBMC/well). 7 and 14 d later, half of the medium was replaced with RPMI medium sup-
plemented with 10% FCS and 200 U/ml rIL-2, and 2 x 105 irradiated PBMC perwell from
two different healthy donors. 3-4 wk after the initial incubation, TIL from the proliferating
microcultures were transferred into 24-well culture plates in the presence of 105 irradiated
autologous tumorcellsperwell. Stimulation with irradiated autologous tumorcellswasrepeated
every 10-14d. Double coloranalysis ofsurface antigens was performedwith FITC-conjugated
anti-CD16 mAb and PE-conjugated anti-Leu 4 mAb, or with FITC conjugated anti-CD8
mAb and PE-conjugated anti-CD4 mAb as reported previously (6).
Results
Kinetic Study of rIL-2-induced Expansion.
￿
In all 12 metastatic melanomas tested,
a substantial proportion of TIL was present in tumor cell suspensions (Table I).
The ratio of lymphocytes to tumor cells ranged from 0.03 to 1.25 with an average
ratio of 0.40 t 0.37. By fluorescence analysis, TIL consisted of 78 t 11% CD3'
T cells, 33 t 10% CD4+, and 49 t 17% CD8' (Table I). Their CD4/CD8 ratio
was 0.67. TIL from all 12 patients increased in number when cultured with rIL-2
(200 U/ml) alone, and reached maximum propagation at an average of 43 d (Table
I). The mean n-fold increase was 1,543, ranging from 840 to 3,675. The number
of resident TIL isolated from melanoma tumors was in the range of 1.0 x 106 to
2.4 x 109 cells, and thus the expected total numbers of rIL-2-expanded TIL ranged
from 1.0 x 109 to 2.0 x 1012 cells (mean 3.0 x 1011 cells) (Table I). These rIL-2-
expanded TIL consisted of 97 t 3% CD3+, 39 t 5% CD4+, and 59 t 25%
CD8+ cells (CD4/CD8 ratio = 0.60).
TIL from 9 of 12 patients with metastatic melanoma rapidly and consistently in-
creased in number from the initiation of culture with rIL-2 alone. A representative1422 CYTOTOXIC T LYMPHOCYTES IN METASTATIC MELANOMA
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result is shown in Fig. 1 A. TIL from patient 4 increased by 17-fold at 14 d in the
presence of rIL-2 (200 U/ml), by 148-fold at 27 d, by 588-fold at 36d, by 1,470-fold
at 47 d, and by 3,675-fold at 59 d. These rIL-2-expanded TIL displayedhigh levels
of autologous tumor lysis as early as 5 d in culture (Fig. 1 A). Cytotoxic activity
was consistent for as long as 59 d in culture. In contrast, there were very low levels
ofallogeneic melanoma lysis, and only during the first 5-17 d in culture (Fig. 1 A).
After maximum expansion with rIL-2, the number of TIL decreased gradually in
culture with aconcomitantdecrease in cytotoxicity. Coexisting tumor cells were com-
pletely eliminated within 10 d in culture with rIL-2 (data not shown). In control
cultures without rIL-2, the number of TIL decreased and disappeared within 10
d while the number of tumor cells essentially remained the same for 7-10 d (data
not shown).
TIL growth from the other three patients with metastatic melanoma (2, 5, and
9) was delayed when compared with that ofthe nine patients. The kinetics of one
of the three is shown in Fig. 1 B. TIL from patient 2 increased in number in the
presence of rIL-2 by fivefold at 17 d, by 96-fold at 31 d, and by 960-fold at 43 d
with consistently high levels of CTL activity restricted to autologous tumor cells
(Fig. 1 B). There was weak allogeneic tumor lysis that disappeared after 5 wk in
culture. After maximum expansion, the number of TIL decreased gradually, ac-
companied by decreased cytotoxicity. Coexisting tumor cells from these three pa-
tients proliferated in culture with or without rIL-2. Further, there were substantial
numbers of dead TIL and tumor cells in culture with rIL-2. Therefore, TIL and
certain tumor cells that were not adherent to the culture plate were applied to a
Ficoll-Hypaque density cushion to isolate live cells. The procedure was repeated
several times during the first few weeks ofthe culture, and the cells were continued
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FIGURE 1.
￿
Kinetic analysis of
rIL2-induced propagation of
TIL. Cell suspension of TIL
andtumorcells from patients 4
(a) and 2 (b) were incubated in
RPMI 1640 medium supple-
mented with 10% FCSand200
U/ml rIL-2 for 70 d. Every 7-10
d, viable TIL and tumor cells
were enumerated. Thenumbers
of TIL were used to calculate
their fold expansion (®). The
cytotoxicity against autologous
(") or allogeneic (A) noncul-
tured melanoma tumor cells
wastested in a 4-h"Cr-release
assayat effectontarget (E/T)ra-
tios of 20, 10, and5. Values rep-
resent lytic units (LU/106
effectors). One LU wasdefined
as the number of effector cells
that lyse 30% of 104 target
cells.ITOH ET AL.
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in culturewith rIL-2 (200 U/ml). Thereafter, TIL consistently increased in number
in culture with rIL-2 alone, whereas the proportions of tumor cells decreased and
disappeared within 4 wk of culture. In the control cultures without rIL-2, tumor
cells vigorously increased in number, while TIL disappeared within 10 d (data not
shown).
rIL-2-activated TIL from all patients with melanoma (n = 12) primarily lysed
only autologous tumor cells. None of the other targets tested, such as freshly pre-
pared autologous PBMC, allogeneicmelanoma orrenalcell carcinomacells or K562
targets, showed higher susceptibilitytorIL-2-activatedmelanoma TIL as compared
to autologous melanoma tumor cells. Representative results are shown in Table II.
Lymphocytes from LNwith melanomametastasis poorly respondedto rIL-2 (2.7-
fold maximum expansion at 14 d in culture) (Table I). In contrast, the number of
TIL from sarcoma increased in culture with rIL-2 by more than 5,000-fold(3,059-
7,700, mean; 5,413), which is significantly higher (P <0.01) than that of TIL from
metastatic melanoma (Table I). rIL-2-activated TIL from three renal cell carcinomas
increased in number by -1,000-fold in culture with rIL-2.
KineticStudy ofCytotoxicity.
￿
Freshly isolatedTIL preparations didnot lyse autolo-
gous melanoma tumor cells (data not shown). rIL-2-activated TIL from all 12 mela-
nomapatients tested inthis study demonstrated stable andpotent CTL activity against
autologous tumor cells. Cytotoxicity against allogeneic tumor cells was at least 10
times lower than against autologous tumor cells. Representative results from nine
patients are shown in Fig. 2. During 2-3 or4-6 wk in culture with rIL-2, TIL from
all patients were consistently cytotoxic for autologous targets (mean LU/106 effectors
during 2-3 wk: 44, range of4-400; mean LU during 4-6 wk: 44, 9-100) (Fig. 2).
There was very low (in five ofnine patients) or no (in four ofnine patients) cytotox-
icity against allogeneic melanoma cells. Tumor cells were no longer present in cul-
ture with rIL-2 after 3 wk. Thus, rIL-2-activated TIL can be propagated during
4-6 wk in culture with rIL-2 alone in the absence ofautologous tumor cellswithout
lossoftheir specific CTLactivity. During the 7-9 wk inculturewithrIL-2, the levels
TABLE II
Autologous Tumor-specific Cytotoxicity Mediated by rIL2-activated Melanoma TIL
TIL from melanoma patients (n = 6) were cultured with rIL-2 (200 U/ml) for 3-4 wk, and then were
tested for their cytotoxicity against a panel of targets shown above at an E/T ratio of 10:1 in triplicate.
Values represent the mean t SD of percent lysis.
' Freshly prepared PBMC were used as targets.
I Renal cell carcinoma.
S Significantly (p < 0.001) higher than those of the others (student's two-tailed t test).
Percent-specific lysis of targets (E/T = 10)
TIL from Autologous Autologous Allogeneic tumor cells
patient tumors PBMC" Melanoma A Melanoma B RCCI K562
1 55.7 t 5.5S 0 0 ND 2.5 t 1 .0 3 .0 t 1 .0
2 35.2 t 3.45 3.1 t 1 .0 4.3 f 2 ND 0 2 .5 t 1 .1
5 39.4 t 6.45 0 0 6.1 t 2.1 ND ND
7 44.9 t 8.5S ND 8.2 t 3.1 6.8 t 1 .2 ND 10.1 t 3 .5
11 35.3 t 4.1S ND ND 0 ND 4.5 f 3 .1
12 49.3 t 5.OS ND 10.1 t 4.1 5.2 t 3 .0 ND ND1426
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500
FIGURE 2.
￿
Kinetic analysis of cytotoxicity.
TIL from nine metastatic melanomas were
incubatedwith rIL-2(200 U/ml)for9wk, and
tested everyoneor twoweeks forcytotoxicity
against fresh autologous ([I) andallogeneic
(0) melanoma cells in 4-h "Cr-release as-
says. Thelevels ofcytotoxicity were expressed
as LU/106effectors. The meansof LU during
2-3, 4-6, and 7-9 wk from each patient are
depicted. One or two allogeneic targetswere
used to evaluate cytotoxicity againstallogeneic
tumorcells, andthe mean levels oflysis ofal-
logeneic tumor cells at the three different
periods were shown. Thelevels ofautologous
tumorlysis were at least10 timeshigher than
allogeneic tumorlysisduringtheentire incu-
bation period.
ofcytotoxicity against autologous tumorcells decreased gradually (mean LU:21, 9-35)
accompaniedby a reduction ofthenumberofcells (Figs. 1 and 2). None ofthe TIL
in 0 of 7 patientslysed allogeneictumor cells during the period of7-9 wk in culture
(Fig. 2). It should be emphasized that rIL-2-activated TILfromall 12 patients studied
here displayed significantly higher cytotoxicity against autologous tumorcells than
that against allogeneic melanoma tumorcells. Allogeneic melanomacells from three
to six different patientswere used as targetsto investigate allogeneic tumor cell lysis
during theentire culture period for9wk. Therefore, it appears that melanoma TIL
exhibit specific cytotoxicity after culture with rIL-2.
CTL activity restricted to fresh autologous melanoma cells largely resided in the
CD8+CD4- T cells, since treatment of effectors from three out of three patients
with anti-CD3(OKT3) mAbor anti-CD8(OKT8) mAb plus rabbit complement abol-
ished orsignificantlydecreasedthe cytotoxicity, respectively (datanot shown). Treat-
ment with anti-CD4(OKT4) mAb plus complement did not significantly decrease
the cytotoxicity.
Cytotoxicity of TILfrom Metastatic Melanoma andfrom other rIL-2-activated Lympho-
cytes. The mean ± SDofautologous melanomacelllysis mediated by rIL-2-activated
TIL from patients (1-9) tested in this study was 44 ± 40 LU/106 effectors at 2-3
wk as shown in Fig. 2, 44 t 30 at 4-6 wk (Fig. 3) and 21 t 11 at 7-9 wk. Against
allogeneic melanoma cells values were 2.3 ± 4.9 (at 2-3 wk), 0.9 t 1.7 (at 4-6 wk)
(Fig. 3), and <0.1 (at 7-9 wk). Thus, autologous melanoma cytotoxicity by rIL-2-
activatedTIL remained consistently highduring the entire cultureperiod with rIL-
2 (Figs. 2 and 3). In contrast, rIL-2-activated lymphocytes from melanotic LN had
both diminished autologous (0.2 LU/106 effectors) and Alogeneic (0.7 LU) tumor
cell lysis during 2-3 wk in culture with rIL-2 (Fig. 3). Thereafter, lymphocytes de-
creased in number and ceased growing in culture with rIL-2. rIL-2-activated TIL
from sarcomas displayed only moderate autologous (2.9 LU) and allogeneic (3.3
LU) tumor cell lysis (Fig. 3). rIL-2-activated TIL from renal cell carcinoma were
potently cytotoxic against both autologous (35 LU) and allogeneic (35 LU) tumor
cells. rIL-2-activated PBMC (LAK cells) from patients with metastatic melanoma
were not very cytotoxic for allogeneicmelanoma cells after 3 d in culture with rIL-2
(2.8 LU) (Fig. 3). As previouslyreported (15), LAK activity againstautologous mela-
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FIGURE 3.
￿
Cytotoxicity by rIL-2-activated
lymphocytes from different sources. rIL-2-
activatedlymphocytes from the sources shown
were tested for cytotoxicity against fresh au-
tologous (p) or allogeneic (®) tumor cells.
Incubation period with rIL-2 (200 U/ml) was
4-6wk forTILfrom melanoma, sarcoma, or
renal cell carcinoma, 2-3wk for lymphocytes
from LN,or 3 dforPBMC from patients with
metastatic melanoma. Levels of cytotoxicity
were expressed as mean of LU/106 effectors.
Levels of autologous tumor cell lysis by ef-
fectors from melanomas were significantly
higher than those of the others except with
those by rIL-2-activated TIL from renal cell
carcinoma (P < 0.001; Student's two-tailed t
test).
noma cells was not high (mean ± SD of LU 106 effectors; 1.4 t 2.0 at 3 d in cul-
ture with 20 U/ml rIL-2) and was not significantly different from allogeneic tumor
cell lysis (16). These resultssuggest that TIL from metastaticmelanomashave unique
characteristicsdifferentfromlymphocytes obtained from othersources and thus can
be propagated in vitro with rIL-2 alone in larger numbers with high levels ofcytol-
ysis restricted to fresh autologous melanoma cells.
MHC-nonrestricted Cytotozicity by PBMCCultured with Autologous Tumor Cellsand rIL-2.
We investigatedwhetherPBMC exhibit autologous tumor-specific CTL activity when
initially cultured with fresh autologous tumor cells followed by incubation with a
low dose of rIL-2 (Table III). PBMC were incubated with fresh autologous tumor
TABLE III
MHC-nonrestricted Cytotoxicity by PBMC Stimulated with Autologous Tumor Cells and rIL2
PBMC from patients with metastatic melanoma (n = 4) were incubated with autologous tumor cells at an
effector/stimulator ratio of 2:1 in the presence of20 U/ml rIL-2 for 30 d. Cell suspensions of melanoma tumors
from the same patients (n = 3) were incubated with 20 U/ml rIL-2. At different times of incubation periods,
cells were washed and were tested for cytotoxicity against autologous andtwodifferent allogeneic melanoma
cells and the K562 targets at E/T ratios of 10:1 and 2 .5:1 in a 4-h 51Cr-release assay. Half the volume of
the medium was replenished every 3-5 d with RPMI 1640 medium supplemented with 10% FCS and 20
U/ml rIL-2 . Tumor cells in culture disappeared within 7-14 d. PBMC were not restimulated with autolo-
gous tumor cells. Values represent mean of percent-specific lysis from the triplicate determinations.
Patients Lymphocytes
Incubation
time
melanoma
10
Autologous
cells
2.5
melanoma
10
Allogeneic
A
2.5
melanoma
10
Allogeneic
B
2.5
K562
10 2.5
d
A PBMC 6 19 6 20 7 ND ND 25 10
PBMC 20 12 23 12 4 ND ND 45 15
PBMC 30 2 0 6 4 0 0 ND ND
B PBMC 20 3 1 11 5 7 4 29 18
TIL 20 25 18 12 6 5 3 ND ND
C PBMC 9 38 17 20 8 15 4 ND ND
TIL 9 35 19 5 4 0 0 ND ND
D PBMC 11 11 6 42 13 16 8 41 25
TIL 11 29 18 14 5 8 5 8 31428
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cells at a ratio of2:1 in the presence of20 U/ml rIL-2. Cell suspensions ofTIL and
tumor cells from the same patients were incubated with 20 U/ml rIL-2. PBMC or
TIL were replenished with freshmediumwith rIL-2, but were not restimulated with
autologous tumor cells. Only in one ofthe four patients, PBMC exhibited higher
levels ofautologous tumor cell lysis rather than those ofallogeneic melanoma cells.
PBMC from the other three patients exhibited MHC-nonrestricted cytotoxicityeven
when cultured for>20-30 d. PBMC exhibited lower cytotoxicity when cultured for
longer periods. PBMC from two offour patients (Exp. C and D) did not increase
in numberin culture with rIL-2 after9 (Exp. C) or 11 (Exp. D) d. Thus, the cytotox-
icity was not measurable. These results suggest that PBMC primarily contain few
T cells capable of exhibiting specific CTL activity after the initial stimulation with
fresh autologous tumor cells followed byincubation with rIL-2. In contrast toPBMC,
rIL-2 (20 U/ml)-activatedTIL from thesame patients (n = 3) displayed muchhigher
cytotoxicity against autologous tumor cells than that against allogeneic melanoma
cells (Table III). Autologous tumor cells were present in the initial culture ofTIL
with rIL-2, and rIL-2-activated TIL were not restimulated with autologous tumor
cells. The stimulation conditions of PBMC and TIL were almost identical.
rIL-2-activated CD16+ NK Cells in TIL.
￿
We investigated ifCD3-CD16+ NK cells
were present in the infiltrate ofsolid tumors and responsible for autologous tumor
lysis. Freshly prepared TIL from metastatic melanoma (n = 11), contained 80%
CD3+ T and <2% CD16' NK cells. Those from sarcoma (n = 5) or renal cell car-
cinoma (n = 3), contained 40% CD3' T and 6% CD16+ NK cells, or 75% CD3+
T and 5% CD16+ NK cells, respectively. rIL-2-propagated TIL consisted of >98%
CD3` T and <0.lolo CD16+ NK cells in metastatic melanoma (n = 12), 50% CD3+
T and 21% CD16+ NK cells in sarcoma (n = 4), or 75% CD3+ T and 25% CD16+
NK cells in renal cell carcinoma (n = 3) after 2-4 wk in culture. There were <2° Io
CD3+CD16+ T cells as determined by two-color immunofluorescence analysis.
After 4-6 wk in culturewith rIL-2, TIL from sarcoma or renal cell carcinoma con-
sisted of >96o 7c CD3+ T cells and <2% CD16+ NK cells in rIL-2-activated TIL
(datanot shown). CD16+ NK cells and CD16- (CD3+ ) T cells from rIL-2-activated
TIL (cultured for3 wk) from apatientwith renalcell carcinomawere purified using
a cell sorter, and the individual populations were tested for cytotoxicity (Table IV).
Purified CD16+ NK cells were potently cytotoxic for autologous renal cell carci-
noma, allogeneic melanoma, and K562 target cells (Table IV), and allogeneic renal
cell carcinoma cells (data not shown) . CD16-CD3+ T cells from renal cell carci-
noma also displayed MHC-nonrestricted cytotoxicity. Cytotoxicity by CD16-CD3+
T cells was lower than purified CD16+ cells or unseparated effector cells, but higher
than rIL-2-activated PBMC. Both CD16+ NK and CD16-CD3+ T cells prolifer-
ated in response to rIL-2 (Table IV). The results suggest that there may be no con-
tribution from NKcellsin melanomatoautologous tumorcelllysis, but rIL-2-activated
CD16+ NK cells from renal cell carcinoma have the capacity to lyse both autolo-
gous and allogeneic tumor cells.
Clonal Analysis of TIL.
￿
To investigate immunological properties of TIL at the
clonal level, we carried out limiting dilution analysis (Table V). TIL from a patient
with metastaticmelanoma and from apatientwith renal cell carcinomawere cloned
by limiting dilution and tested for cell surface antigen expression and cytotoxicity
against fresh autologous or allogeneic tumor cells, or K562 targets (Table V). TILITOH ET AL.
TABLE IV
MHC-nonrestricted Cytotoxicity by rIL2-activated CD16 + NK or CD16 - CD3+ T cells
Obtainedfrom the Infiltrate of Renal Cell Carcinoma
1429
TIL from a patient with renal cell carcinoma (RCC#1) were cultured with rIL-2 (200 U/ml) for 3 wk. PBMC
from a healthy donor were cultured with rIL-2 (200 U/ml) for 3 d. rIL-2-activated TIL were stained with
FITC-conjugated anti-Leu-lla (CD16) mAb for 30 min at 4°C followed by sorting into positive and nega-
tive fractions using a cell sorter (EPICS C). These sorted fractions and unseparated TIL were incubated
overnight in culture with 200 U/ml rIL-2 and then tested for surface antigen expression, proliferation, and
cytotoxicity against autologous fresh RCC cells, allogeneic fresh melanoma cells, and K562 target cells in
a 4-h 5'Cr-release assay. [3H]TdR (0.5 pCi/well) was added to wells containing 104 cells/well/0.2 ml 6 h
before harvesting, and values represented the mean t SD oftriplicate determinations. Cytotoxicity was ex-
pressed as LU per 106 cells.
were plated at 8-0.5 cells/well. Proliferating microcultures were <10%. All these TIL
expressed the CD3 antigen, and either CD4 or CD8 antigens on the cell surface.
Theseresults assuredhigh probabilityofclonality. 8ofthe 10 clones from metastatic
melanoma displayed significant lysis only against autologous tumor cells (>10% lysis
at an E/T ratio of8), while only 2 of the 10 exhibited more than 10% lysis against
autologous and allogeneic tumor cells (TXRC3, renal cell carcinoma cells). None
ofthem showed NK activity against K562 targets. 3 of10clones vigorously prolifer-
ated in culture withrIL-2. The means t SDofpercent lysisfromthesethree clones
at E/T ratios of 20:1, 10:1, and 5:1 against autologous tumor cells were 31.8 t 7.2,
25.9 ± 5.6, and 22.2 t 3.6, respectively. Those against allogeneic melanoma cells
were 2.6 t 1.8, 1.7 ± 0.6, and 1.0 t 1.0, respectively, and they did not lyse al-
logeneic renal cell carcinoma targetsatany E/Tratios tested. In contrast, all 13 cloned
TIL from renalcell carcinomalysedautologous renalcarcinomacells and allogeneic
melanomatumorcellsequallywell (Table V). 3 ofthe 13displayed NKactivity against
K562 targets. 1 ofthe 13 cloned TIL vigorously proliferated in culture with rIL-2,
and this cloned Tcell exhibited cytotoxicity against allogeneic renal cell carcinomas
as well asautologous renal carcinomaandallogeneic melanomacells (data not shown).
Role of 7CR-a//3.
￿
Addition ofanti-CD3 mAb(OKT3 mAb) or antiTCRa/(3 mAb
(WT31 mAb) to the 4-h "Cr-release assay significantly decreased CTL activity
against autologous tumor cells mediated by TIL from all six melanoma patients
tested, while anti-CD4 mAb did not affect the cytotoxicity in any (Fig. 4 A). Anti-
CD8 mAb inhibited CTL activity by 70% in one of six patients (patient 8) and
modestly in patient 2 (Fig. 4A). None ofthe mAb inhibited LAK activity mediated
by PBMC when added to the assay (data not shown). These results suggest that
TCRa/0 on rIL-2-activated TIL is involved in autologous tumor cell-specific CTL
activity. rIL-2-dependent proliferationofcultured TIL wasalsoinhibited byadding
rIL-2-activated cells
Percent
CD3
positive cells
CD16
Proliferation
(CPM 104cells/well)
Cytotoxicity'
Autologous
RCC
(LU/106 cells)
Allogeneic
Melanoma
against
K562
Unseparated TIL
from RCC#1 71 30 28,586 f 4,291 30 22 140
CD16' NK cells
from RCC#1 4 99 32,755 t 625 34 26 1,670
CD16 - (T3') T cells
from RCC#1 98 0 31,462 t 160 16 12 57
PBMC (LAK cells) 93 5 ND 2 1 331430
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TABLE V
Limiting Dilution Analysis of TIL from a Patient with Metastatic
Melanoma or Renal Cell Carcinoma
Clonal analysis of TIL from a patient with metastatic melanoma or renal cell
carcinoma was evaluated by limiting dilution by a modification of the method
described by Moretta et al. (14). Briefly, different numbers (8,4,2,1, and 0.5)
of fresh TIL per well of 96 U-bottomed microplate were incubated with RPMI
medium supplemented with 10% FCS, 200 U/ml rIL-2, 10 wg/ml PHA, and
10 ng/ml phorbol 12-myristate 13-acetate (PMA), in the presence of x-irradiated
(7,000 rad) PBMC from two different healthy donors (2 x 105 PBMC/well) .
7 and 14 d later, half of the medium was replaced with RPMI medium sup-
plemented with 10% FCS and 200 U/ml rIL-2, and 2 x 105 x-irradiated PBMC
per well from two different healthy donors. 3-4 wk after the initial incubation,
proliferating TIL were transferred into 24-well culture plates in the presence of
105 x-irradiated autologous tumor cells per well. Stimulation with x-irradiated
autologous tumor cells was repeated every 10-14 d. Double-color analysis of sur-
face antigens was performed with FITC-conjugated anti-CD16 mAb and PE-
conjugated anti-CD3 mAb, or with FITC-conjugated anti-CD8 mAb and PE-
conjugated anti-CD4 mAb as reported previously (6). Cytotoxicity against
autologous, allogeneic tumor cells, or K562 was repeatedly investigated in a 4-h
5'Cr-release assay. Representative results are shown.
anti-CD3 mAb or antiTCRa/D mAb to the culture (Fig. 4B). Anti-CD8 mAb(Fig.
4 B) or anti-CD4 mAb (data not shown) did not inhibit rIL-2-dependent prolifera-
tion ofTIL from any patients tested. Anti-CD3 or antiTCR-a/0 alone did not in-
duce the proliferation ofTIL. In contrast, PBMC from one patient showed high
levels ofanti-CD3- or rIL-2-dependent proliferation, as wellas modest levels ofanti-
TCR-a/(3 mAb-induced proliferation (Fig. 4 B).
Patient
Clone
No.
Surface antigen
CD3 CD4 CD8
Percent
Autologous
tumors
lysis (E/T =
Allogeneic
tumors
8)
K562
Metastatic 1 99 0 99 19.4 4 .7 4 .6
melanoma 2 99 0 99 19.0 4 .8 2 .7
(TXM2) 3 99 0 96 23.3 4.9 9 .5
4 99 96 0 7.8 3 .0 4.0
5 99 0 99 21 .3 6.4 4 .2
6 99 99 0 10.8 15 .9 0
7 98 98 0 18.6 6 .1 2 .0
8 98 98 0 22.4 21 .2 1 .6
9 99 99 0 26.7 7 .8 0
10 99 98 0 12.1 3.6 0
RCC 1 99 98 0 18.9 20 .0 2 .6
(TXRC3) 2 99 99 0 23.8 17.5 19.9
3 99 98 0 17.3 14.4 2 .0
4 99 0 98 18 .7 19 .8 20 .3
5 98 0 98 10.6 15.6 1 .0
6 99 98 0 18 .1 18 .1 3 .0
7 99 90 0 21.0 21 .2 2 .1
8 99 98 0 23.9 23 .2 0.9
9 99 99 0 27 .0 19 .5 5 .9
10 98 97 0 24.1 17 .6 4 .2
11 98 97 0 18.9 16 .9 18 .5
12 99 98 0 13.8 14 .3 5 .2
13 99 98 0 23 .7 13 .9 1 .9Treatment
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FIGURE 4.
￿
Inhibition of the cytotoxicity and proliferation by anti-CD3 mAb or antiTCRa/p
mAb (WT31 mAb). rIL-2-activated TIL from six different melanoma patients were incubated
for more than 30 d with 200 U/ml rIL-2. (A) Cytotoxicity against autologous tumor cells medi-
ated by rIL-2-activated TIL was determined in a 4-h 5ICr-release assay at an E/T ratio of 20
in the presence ofanti-CD3 mAb, anti-CD4 mAb, anti-CD8 mAb (1 :20 dilution of ascitic fluid),
antiTCRa/p mAb (WT31 mAb, 1 :20 dilution of 1 mg/ml purified IgG) or normal mouse IgG
(1:20 dilution of 1 mg/ml IgG). Effector cells were pretreated for 30 min at room temperature
with mAb followed by addition oftarget cells. (B) These rIL-2-activated TIL from three patients
and PBMC from a single patient were incubated with 200 U/ml rIL-2 for 3 d (105 lympho-
cytes/well in flat-bottomed microtiter plates) in the presence or absence of the mAb indicated
in the figure. 0.4 gCi of[3H]TdR was added to each well 6 h before harvesting. Values represent
mean ± SD ofpercent lysis or counts per minute oftriplicate determinations from six and three
different patients, respectively. Statistical analysis was carried out by the Student's two-tailed t
test where the percent lysis in effectors treated with normal mouse IgG was compared to that
exhibited by effectors treated with mAb. Counts per min of cells cultured with rIL-2 alone was
compared with those cultured with rIL-2 and mAb.
Role ofMHCAntigens.
￿
To investigate the involvement ofMHC antigens in CTL
activity, either effector cells or fresh autologous tumor targets from patient 2 were
pretreated for 30 min with various mAb, washed, and tested for CTL activity or
susceptibility to lysis, respectively (Table VI). Pretreatment of effectors with anti-
CD3 or antiTCRa/a mAb moderately decreased CTL activity against targets
pretreated with control IgG2a, anti-CD3 mAb, or anti-HLA-DR mAb. Pretreat-
ment oftargetswith anti-HLA-A, -B, and -C mAb, butnot with theothers, inhibited
CTL activity by -70%. However, it did not affect LAKactivity mediated byrIL-2-
activated PBMC. Pretreatment of effectors with anti-CD3 or antiTCRa/R mAb
completely abolished CTL activity against targetspretreated with anti-HLA-A, -B,1432
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and -C mAb but not with anti-HLA-DR mAb. Theseresults suggest thatboth TCR-
a/ß on TIL effectors from patient 2 and HLA-A, -B, and -C antigens on fresh autol-
ogous tumor targets are involved in specific CTL activity. In contrast, anti-HLA-
DRmAb but not anti-HLA-A, -B, and -C mAb inhibited specific CTL activity medi-
ated by rIL-2-activated TIL from patient 1 when added to the 4-h "Cr-release assay
(data not shown).
Role ofAutologous Tumor Cells.
￿
Aftermaximumpropagation, TIL from all 12 mela-
noma patients responded poorly to rIL-2 with decreased proliferation and CTL ac-
tivity (Table I, Figs. 1 and 2). However, stimulation of these TIL with both rIL-2
and autologous tumor cells restored cytotoxicity againstautologous tumorcells and
proliferation in all seven cases tested (Fig. 5). Occasionally, stimulation with autolo-
gous tumor cells alone induced CTL activity (in patient 1) and proliferation (in pa-
tients 1 and 4). Addition of medium alone or allogeneic melanoma tumor cells to
the culture resulted inlossofactivity. Stimulation with rIL-2 alone maintained low
but substantial levels oflysis of autologous tumor cells accompanied by low levels
of proliferation. Addition of rIFNy, rIL-1, rIL-3, or rIL-4 with or without rIL-2
did not increase either CTL activity orproliferationoflong-termcultured TIL (data
not shown). Addition ofanti-CD3 mAb as well as antiTCRa/ß mAb to the culture
of these TIL with rIL-2 and autologous tumor cells abolished both CTL activity
andproliferation (data not shown). These results suggest that both rIL-2 and autol-
ogous tumor cells are required for further propagation oflong-term cultured TIL,
and that TCR-a/ß on these TIL is involved in the recognition of fresh autologous
tumor cells.
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Role ofautologous
tumor cells on TIL activation.
rIL-2-dependent TILfrom sev-
en different melanoma patients
incubated with rIL-2 for >40-
60 dwere incubated at 1051ym-
phocytes/wellin 96-wellmicro-
titerplates with medium alone,
autologous tumorcells alone, al-
logeneic tumorcellsalone, rIL-
2(200 U/ml)alone, both rIL-2
and autologous tumorcells, or
both allogeneic tumorcells and
rIL-2. Tumor cells were irradi-
ated with 10,000 rads and cul-
tured with TIL as stimulators
at aTIL/tumorcell ratio of 1:1.
The cytotoxicity against autol-
ogous tumor cells was inves-
tigated after 5 d in culture in a
4-h 5(Cr-release assay at three
different E/T ratios, and the
results were expressed as
LU/106effectors. The results of
proliferation were expressedas
mean ofcountsperminute from
triplicate cultures. Counts per
minute of irradiated tumorcells
alone were <500 (data not
shown).
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￿
rIL-2-dependent TIL from all
three melanoma patients whose responsiveness to rIL-2 was restored after stimula-
tion with autologous tumor cells (Fig. 5), expressed IL-2 receptor (IL-2R) (Tac an-
tigen) on the surface after stimulation with autologous tumorcells alone (Fig. 6 A).
Addition ofrIL-2 or allogeneic tumor cells did not induce IL-2R expression. rIL-2
alsodid not have any synergistic effect on IL-2R expression induced by stimulation
with autologous tumor cells (Fig. 6 A). These results suggest that stimulation with
autologous melanoma cells is sufficient to induce IL-2R on TIL. A representative
histogram is shown in Fig. 6 B. Thus, addition of autologous tumor cells induced
IL-2R expression on rIL-2-activated TIL by 65% at 16 h and by 92% at 96 h of
incubation. rIL-2 alone or allogeneic melanoma tumor cells (Fig. 6B)orK562 target
cells (data not shown) failed to induce IL-2R expression. The expression ofIL-2R
induced by adding autologous tumor cellsdisappeared after 14-18 d in culture con-
taining rIL-2 and without restimulation (data not shown) . These results suggest that
IL-2R expression ofrIL-2-activated TIL from metastatic melanoma is upregulated
by fresh autologous tumor cells.
Discussion
TIL from metastatic melanomas increased in number by X1,000-fold in culture
with rIL-2 alone. Although autologous melanoma cellswere initiallypresent in TIL
cultures with HL-2, they were not detectable after 3 wk in culture. Therefore, TIL
IL2R (Tac) Positive Cells (N = 3, Mean t SD)
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Regulation ofIL-2
receptor expression by autolo-
gous tumor cells. Long-term
(>40 to 60 d) cultured TIL
from three melanoma patients
expanded in thepresence ofrIL-
2 were incubated with medium
alone, fresh autologous tumor
cells alone, allogeneic tumor
cells alone, rIL-2 (200 U/ml)
alone, rIL-2 and autologous
tumor cells, or rIL-2 and al-
logeneic tumor cells. Tumor
cells were irradiated (10,000rad)
and added to the culture at an
effector/stimulator ratioof 1:1 .
After16 h(A andB) or 96 h(B),
the cells were washed and in-
cubatedfor30 minat 4°C with
PE-conjugated anti-IL-2 recep-
tormAb(antiTacmAb, Becton
Dickinson). The levels of ex-
pression of IL-2R were ana-
lyzed using flow cytometry
(EPICS C). For control, cells
were stained with PE-conju-
gatedirrelevant mAb (antiThy
1.2 mAb, Becton Dickinson)
and the percentage of positive
cells was between 3 and 5%
(data not shown).1434
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proliferated in culturewith rIL-2 alone at least forseveral weeks (4-6 wk). Cytolysis
restricted to fresh autologous tumor cells was consistently high during culture with
rIL-2, in agreement with our previous observation (1) and those ofothers (10). Gener-
ally, CTL induced in vitro requireboth the antigenic stimulation and IL-2 fortheir
activation. However, rIL-2-activated TILfrom metastatic melanoma have the ability
to proliferate for a substantially long period in culture with rIL-2 alone in the ab-
sence ofautologous tumor cells without loss of their specific CTL activity. Stimula-
tion with autologous tumorcells facilitated furtherexpansion of these TIL with specific
CTL activity. This specific cytotoxicity may be a consequence of in vivo priming
and therefore may not be induced during in vitro culture with rIL-2. Lymphocytes
from melanotic LN neither increased in large numbers nor exhibited specific CTL
activity, even afterculture with rIL-2 in the presence of autologous tumor cells. rIL-
2-activated PBMC (LAK cells) exhibited modest proliferation in response to rIL-2
(17) and did not exhibit MHC-restricted cytotoxicity (4-9, 15, 16). rIL-2-activated
TILfrom theother solid tumors such as sarcoma(Fig. 3), renal cell carcinoma(Fig.
3; Table IV; Reference 18), lung cancer (19), carcinomas of the head and neck (20)
did not exhibit autologous tumor cell-specific CTL activity. All these results suggest
that TILfrom metastatic melanomas have unique characteristics different from lym-
phocytes obtained from other sources, and thus can be propagated in larger numbers
with autologous tumor cell-specific CTL activity in vitro with rIL-2 alone.
The results obtained from limiting dilution clones were consistent with those ob-
tained from the bulk cultures of TIL. Thus, cloned cells from melanoma TIL dis-
played cytotoxicity restricted to autologous tumor cells, while those from renal cell
carcinoma TIL lysed autologous and allogeneic tumor cells. The major difference
in renal cell carcinoma TIL obtained from the limiting dilution and those from the
bulk culture is the absence of CD16` NK cells at the clonal levels. Although the
exact mechanisms involved are unknown, different culture conditions may account
in part for the differences. Only rIL-2 was used for the bulk culture of TIL, while
10 ug/ml PHA, 10 ng/ml PMA, and irradiated PBMC from two different healthy
donors were used for the limiting dilution assays in addition to rIL-2. These re-
agents may selectively propagate T cells but not NK cells.
One explanation forthe unique immunological specificity of TILfrom metastatic
melanoma is the potential presence of precursor CTL sensitized in vivo to autolo-
gous tumorcells. Exposure to rIL-2 aloneinducesdifferentiation into mature CTL.
Freshmelanoma cellsexpresstumor-associated antigens (TAA) on the surface defined
by several mAb such as anti-GD3 or p97 mAb (21, 22). Fresh melanoma cells may
be more immunogenic than the other solid tumorcells. TIL from metastatic mela-
noma may recognizeantigens expressed on tumor cells in association with self-MHC,
thereby explaining the antigen-specificity andthe MHC restriction. Another expla-
nation is the absence of CD16+ NK cells in the infiltrate of metastatic melanoma.
CD16' NK cells have the ability to respond to rIL-2 and subsequently exhibit
MHC-nonrestricted cytotoxicity (4-9). In contrast to the absence of NK cells in
metastatic melanoma, TIL from sarcoma or renal cell carcinoma contained a sub-
stantial proportion of CD16+ NK cells. These NK cells increased in number in cul-
ture with rIL-2.
It is well known that activation of PBMC from melanoma patients either in sec-
ondary MLC in which EBVtransformed B cell lines were used as stimulators, orITOH ET AL.
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by stimulation with autologous tumor cells in mixedleukocytetumor culture (MLTC)
resulted inthe generation ofcytotoxic Tlymphocyteswith autologous tumor-specific
cytotoxicity (23-28). However, PBMC usually did notexhibit specific CTL activity
after a single stimulation with autologous tumor cells followed by IL-2 (Table III).
In contrast to PBMC, melanoma TIL develop autologous tumor-specific CTL ac-
tivity when cultured with rIL-2. Autologous tumor cells were only initially present
in TIL cultures with rIL-2. These results suggest that PBMC primarilycontainfew
T cells capable ofdifferentiating into autologous tumor-specific CTL after the ini-
tial stimulation withautologous tumorcells followed by rIL-2. An alternative expla-
nation would be that suppressor cells present in PBMC inhibit the differentiation
ofprecursor to effector CTL specific forautologous tumor cells. Repeated stimula-
tion ofT cell cultures or cloned T cells with autologous tumor cells is usually re-
quired for induction and maintenance ofautologous tumor-specific CTL activity
when PBMC from melanoma patients are used as effector cells (23-28). Further-
more, only selective T cell cultures or cloned T cells derived from PBMC display
specific CTL activity, and theothers show MHC-nonrestricted cytotoxicity (23-28).
Incontrast to PBMC, the majority ofT cell cultures and clones derived from mela-
noma tumors display autologous tumor-specific cytotoxicity and repeated stimula-
tion with autologous tumor cells is not required for induction and maintenance of
specific cytotoxicity. All these results suggest that melanoma TIL are different from
PBMC, and contain significantly higher proportions ofcells sensitized to autolo-
gous tumor cells that can differentiate into effector CTL.
rIL-2-activated CD16+ NK as well as CD3+CD16- T cells from renal cell carci-
nomaexhibited MHC-nonrestricted cytotoxicity (Table IV). Itispossiblethat renal
cell carcinoma contains a substantial proportion of blood-derived NK cells, since
the kidney has a rich blood supply, and single-cell suspensions ofrenal cell carci-
noma usually contain many red blood cells and neutrophils. However, cell suspen-
sions ofmetastatic melanoma usually do not contain redblood cells or neutrophils.
Blood-derived T cells also exhibit MHC-nonrestricted cytotoxicity when incubated
with rIL-2 as reported previously (6), as might be the case in rIL-2-activated
CD3+CD16- T cells from renal cell carcinoma. To directly address the difference
ofimmunological properties between TIL and PBMC, we carried outlimiting dilu-
tion analysis using renal carcinoma TIL and PBMC from the same patients. The
majority of PBMC-derived T cell clones with MHC-nonrestriced cytotoxicity ex-
pressed CD4+CD8- antigens, while -50% ofTIL-derived T cell clones expressed
CD4-CD8+ antigens indicating that even in renal cell carcinoma, TIL may be
different from PBMC (unpublished results). An alternate explanation is that TIL
from sarcoma or renal cell carcinomamay contain suppressor cellsthat inhibit rIL-
2-induced differentiation of T cells into autologous tumor-specific CTL.
Normal tissues surrounding the tumor or necrotic areas were carefully removed
fromthe specimen before preparingcell suspensions ofTIL andtumorcells. There-
fore, except with tumors from axillary lesions (patients 4 and 6) or brain (patients
5 and 8), it is very likely that the lymphocytes isolated from the tumor specimen
represent true TIL.
Tumors from patients 1-3, 7, 9, and 10were from subcutaneous lesions, andtherefore
theycouldnotbecontaminated from lymph node lymphocytes. TIL exhibiting specific
cytotoxicity forautologous tumorcells were obtained from allthese six patients whose1436
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specimens were from subcutaneous lesions. Therefore, at least in these six patients,
TIL with specific cytotoxicity were obtained. Tumors from patients 11 and 12 were
from viscera (rectum and lung), and the surrounding tissues were removed before
preparation ofthe cells. Therefore, theycouldnotbe contaminated from lymphnode
lymphocytes or peripheral blood lymphocytes. rIL-2-activated TIL from these two
patients also displayed autologous tumor-specific cytotoxicity.
Cell suspensions ofmetastaticmelanoma from axillary lesions might contain both
TIL and lymphocytes from lymph nodes (LN). However, the substantial numbers
oflymphocytes prepared from these specimens and the majority ofrIL-2-activated
lymphocytes are very likely TILbecause (a) the ratios (1.25 and 1.0) oflymphocytes
totumorcells from thesetwo specimenswere significantlylowerthanthose ofmetastatic
LN (84 t 75) (Table I), (b) ratios of CD4+ lymphocytes to CD8+ lymphocytes
(respectively, 0.9 and 0.25) were lower than those found in metastatic LN (3.0); (c)
The n-fold increase in response to rIL-2 (3,675 and 3,150, respectively) was higher
than that observed in metastatic LN (2.7 f 1.3) and (d) rIL-2-activated lympho-
cytes from these two axillary lesions displayed potent autologous tumor-specific cy-
totoxicity (Fig. 2) while those ofmetastatic LN did not. Melanomaspecimens from
brain lesions from two patients were used in this study. These cell suspensions did
not contain lymph nodelymphocytes; however, they may contain both TILandlym-
phocytesfrom peripheral blood, sincetumorspecimens from these twopatientscon-
tained numerous red blood cells, possibly due to hemorrhage at surgery. However,
on the basis of(a) lymphocyte to tumor cell ratio, (b) CD4/CD8 ratio, (c) the n-fold
increase in response to IL-2, and (d) their cytotoxicity which was restricted against
autologous tumor cells; the substantial numbers of lymphocytes from these speci-
mens and the majority of rIL-2-activated lymphocytes appear to be TIL.
Two different patterns ofgrowth kinetics were observed with TIL from metastatic
melanoma. The first pattern was observed in 9 of 12 cases, and was characterized
by the rapid and consistent growth ofTIL from the initiation ofculture with rIL-2.
The second pattern observed in the other three patients was characterized by the
delayed growth of TIL. There was no apparent difference in surface phenotypes,
cytotoxic potential restricted to autologous tumor cells, or n-fold propagationofTIL
between theformer nine and the latter threepatients (Table I, Figs. 1 and 2). How-
ever, tumor cells from the latter rapidly proliferated in culture without rIL-2, and
increased innumbers evenin thepresence ofrIL-2, whiletumorcells from theformer
did not increase in numbers in culture with rIL-2. The ratios ofTIL to tumor cells
in the latter (0.23, 0.04, and 0.03) were lower than those in the former (0.25-1.25).
This difference might facilitate tumor cell growth, since there were few cytotoxic
TIL per well in culture ofthe latter group. The different capabilities of tumor cells
to proliferate in vitro may account for the different pattern of growth kinetics of
TIL, although the exact mechanism involved is not clear at present.
Antigen-specific CTL activity is usually inhibited by adding anti-CD3 mAb to
theeffector phase ofcytotoxicity (29, 30). However, Muulandcoinvestigators reported
that anti-CD3 mAb did not inhibit the specific cytolysis of autologous tumor cells
mediated byrIL-2-activated TIL from metastaticmelanomas (10). The roleofTCR
on TILwas investigated to elucidate the mechanism involved in the CTL-mediated
recognition offresh autologous melanomacells. Fortheseexperiments, rIL-2-activated
TIL from metastatic melanoma were incubated for >30 d with rIL-2 to induceITOH ET AL.
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cytotoxicity restricted to autologous tumor cells. In all five cases, TCRa/R on rIL-
2-activated TIL was involved in specific CTL activity (Fig. 4 A), as well as in the
rIL-2-dependent proliferation (Fig. 4 B). An additional argument suggesting that
TCR-a/R might be involved in the recognition offresh autologous melanoma cells
byTIL was thefactthat addition ofantiTCRa/D or anti-CD3 mAb to the restimu-
lated long-term cultured TIL resulted in complete inhibition ofthe redevelopment
ofspecific CTL activity and proliferation (Fig. 5 and datanot shown). These results
stronglysuggestthat rIL-2-activated TIL from metastaticmelanomas primarilyrecog-
nize fresh autologous tumor cells through TCRa/p. For the inhibition study, we
used 1:20 dilution of 1 mg/ml ofWT31 mAb or ascitic fluid (10 mg/ml) ofthe anti-
CD3 mAb or the other mAb. In contrast, Muul et al. used as low as 25 jig/ml anti-
CD3 mAb (10). This difference may account for the different results, because high
concentrations of anti-CD3 mAb are required for the inhibition of CTL activity,
as reported by us (31, 32) and others (33).
Our observations on rIL-2-activated melanoma TIL showed much lower ratios
ofCD4 T cells to CD8+ T cells than those reported by Muul et al. (10). Although
exact mechanisms involved are yet unknown, different culture conditions may ac-
count for the difference. Thus, we used rIL-2 alone as the stimulus, while Muul
et al. usedrIL-2 plussupernatants from theculture ofautologous PBMC withrIL-2.
Our results suggest that MHC antigens on fresh melanoma cells may be recog-
nized byautologous CTL (Table VI). Anti-GD2, -GD3, orP97 didnot inhibit TIL-
mediated CTL activity againstautologous melanomatargetswhen added to thecyto-
toxic assayin certainexperiments(data not shown). These results suggest thattumor
antigens defined bythese mAb may not be involved intumor celllysis by autologous
tumor-specific CTL. However, this experimental system may provide a model for
TABLE VI
MHC Antigens on Fresh Tumor Cells are Involved in the Recognition by
rIL-2-activated TIL through TCR
Effector cells or S'Cr-labeled fresh autologous melanoma cells were preincubated for 30 min at 4°C with
the mAb shown above. The cells were washed twice and used as effectors or targets in a 4-h S'Cr-release
assay without mAb at an E/T ratio of 10:1 for TILor 40:1 for LAKcells. Values represent mean t SD
ofpercent lysis from triplicate determinations. Statistical analysis (Student's two-tailed t test) wasdone be-
tween percent lysis of targets treated with control IgG2a (mediated by effectors treated with control IgG2a)
(36 t 6% lysis) and that of each group.
' p < 0.01.
I ¢ < 0.02.
S p < 0.001 .
Effector cells
Pretreatment of
effectors
Percent
Control
IgG2a
lysis of fresh autologous melanoma cells
pretreated with mAb
Anti-HLA- Anti-HLA-
Anti-CD3 DR A, -B,-C
rIL-2-activated Control IgG2a 36 ± 6 36 ± 6 32 ± 5 10 ± 1
TIL Anti-CD3 mAb 18 t 3* 20 t 4t 13 t 7t 2 t 3S
Anti-TCR mAb 14 f 4* ND ND 5 t 3*
Anti-HLA-DR mAb 36 t 11 37 t 12 28 t 10 17 t 1 *
Anti-HLA-A, -B, -C mAb 38 t 12 33 t 11 31 t 2 8 t 2*
rIL-2-activated
PBMC
(LAK cells) None 18 t3 20 t2 18 t3 17 t31438
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thedeterminationofthe molecularbasis ofboth MHC antigens and tumor antigens
recognized by autologous tumor cell-specific CTL.
rIL-2-activated TIL from metastatic melanomas did not express detectable IL-2
receptor (IL-2R) (Tac antigen) on their surface as determined by immunofluores-
cence after 4-9 wk in culture with rIL-2 (data not shown). Paradoxically, there was
rIL-2-dependent proliferationduring 4-6wkin culture with rIL-2 (Fig. 4). Possibly
another IL-2R besides Tac antigen such as the p75 protein (34) plays a major role
as IL-2R on rIL-2-activated TIL from metastatic melanomas at least after 5 wk in
culture with rIL-2. In fact, studies using a chemical crosslinker and 1251-labeled
rIL-2 revealed that the p75 protein on the surface ofthese TIL played a major role
as IL-2R (Yagita, M., K. Itoh, M. Tsudo, L. Owen-Schaub, C. D. Platsoucas, C. M.
Balch, and E. A. Grimm, submitted for publication).
Stimulation oflong-term cultured TIL with autologous tumorcells restored specific
CTL activity and proliferationin response to rIL-2 (Fig. 5). The latter was associated
with IL-2R (Tac antigen) expression (Fig. 6). rIL-2 itself did not affect induction
ofIL-2R on rIl-2-activated TIL. These results suggest that IL-2R (Tac antigen) ex-
pression on rIL-2-activated TIL from metastatic melanomas is upregulated by au-
tologous tumor cells in an autocrine loop.
NK cells responsible for LAK cell precursors (4-9) are usually not detectable in
single-cell suspensions ofmetastatic melanomas as determined by us (in this report,
and reference 1) and others (10), although Kornstein et al. reported the presence
ofB73.1 mAb positive cells (reactive to NKcells, neutrophils and few blood T cells)
in frozen sections ofmetastatic melanomas using an immunoperoxidase technique
(35). However, T cellspredominate in TIL frommetastatic melanomas and are ac-
tivated by adding rIL-2 to the culture to differentiate into mature CTL specific for
autologous tumor cells (1, 10). Substantial numbers of LAK cells were found in bi-
opsies inside renal cancer tumors when they were injected through major tumor-
feeding arteries (36). In contrast, studies ofthe in vivo distribution ofintravenously
infused LAK cells suggested that there was little accumulation ofthe infused LAK
cells in tumor sites (37, 38).
This investigation established several critical characteristics ofT cell response to
melanoma: (a) T cells from metastatic melanomas increased in number by more
than 1,000-fold in culture with rIL-2 alone; (b) rIL-2-activated TIL demonstrated
autologous melanomacell-specificCTLactivity, whereasthose from the othersources
displayedMHC-nonrestricted cytotoxicity; (c) stimulationoflong-term cultured TIL
with fresh autologous melanoma cells restored specific CTL activity and prolifera-
tion in response to rIL-2. Based on the results of this and previous studies (1, 10),
we postulate that rIL-2-activated TIL, compared with LAK cells, are more appro-
priate effector cells responsible for tumor regression in metastatic melanoma pa-
tients, and furthermore, that they will be superior to LAK cells in adoptive im-
munotherapy of metastatic melanoma.
Summary
TIL from metastatic melanoma proliferated by >1,000-fold (840-3,675, mean
1,543) after 6 wk in culture of mixtures ofTIL and tumor cells with rIL-2 alone.
Cytolysis was restricted to autologous tumor cells. CD8+ T cells were the predom-
inant population ofTILbefore and after expansion, and were primarily responsibleITOH ET AL.
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for autologous tumor-specific CTL activity. No other rIL-2-activated lymphocytes
from peripheral blood, lymph nodes with melanoma metastasis, or TIL from sar-
coma or renal cell carcinoma had autologous tumor-specific CTL activity. There
were few or no CD16+ NK cells in TIL from metastatic melanoma before or after
incubation with rIL-2, respectively. However, TILfrom sarcoma or renal cell carci-
noma contained a substantial proportion ofCD3-CD16+ NK cells, which increased
in number in culture with rIL-2. Purified CD16 + NK cells as well as CD3+CD16 -
Tcells from rIL-2-activatedTILofrenal cell carcinoma displayedMHC-nonrestricted
cytotoxicity. At the clonal level as determined by limiting dilution, 8 of 10 clones
from melanoma TILdisplayed cytotoxicity restricted to autologous tumorcells, while
all 13 clones from renal cancer TIL equally lysed autologous and allogeneic tumor
cells. Anti-T cell receptor (TCR)-a/0(WT31) mAbas well as anti-CD3 mAb inhibited
autologous melanoma cell-specific CTL activity mediated by rIL-2-activated TIL
at theeffector phase. These two mAbs also inhibited rIL-2-dependent proliferation
of these TIL when added to the culture. Pretreatment of fresh melanoma cells with
mAb to MHC antigens followed by washing inhibited specific CTL activity. These
results suggest that both TCRa/R on effector TIL and MHC antigens on fresh tumor
cells areinvolved in the specific immune-recognition. Afterreaching maximumpropa-
gation, TIL from metastatic melanoma responded poorly to rIL-2 alone. However,
stimulation with fresh autologous melanoma cells restored both CTL activity and
proliferation in response to HL-2 . The latter is associated with IL-2 receptor (Tac
antigen) expression on the surface. These results indicate that TIL from metastatic
melanomas may have unique characteristics different from lymphocytes obtained
from the other sources, and may containprecursorCTLsensitized in vivo to autolo-
gous tumor cells, and thus can be propagated in larger numbers with rIL-2 alone
while retaining autologous tumor-specific CTL activity.
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